Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × fludrocortisone acetate × Clear all
NCT06104449 2026-04-27

MK-5684-005

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT06136598 2026-03-19

MK-5684-001

Merck Sharp & Dohme LLC

Phase 1 Completed
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT06566989 2024-10-23

MK-5684-008

Merck Sharp & Dohme LLC

Phase 1 Completed
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT06554639 2024-10-15

MK-5684-011

Merck Sharp & Dohme LLC

Phase 1 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡